COPD is a progressive respiratory condition that includes chronic bronchitis and emphysema. It affects over 250 million people worldwide and is a leading cause of disability and death. Standard treatments include bronchodilators, inhaled steroids, oxygen therapy, and pulmonary rehab, but these do not reverse lung damage. Regenerative approaches aim to reduce inflammation and potentially repair airway tissues.
Experimental therapies using stem cells, particularly MSCs, have shown promise in reducing lung inflammation and improving function in animal models and small human trials. Delivery is typically intravenous. Some clinics internationally offer MSC infusions under research or compassionate-use frameworks. Costs vary widely—from $5,000–$20,000 per treatment cycle.
Clinical data is still limited, and outcomes vary. MSC therapy is not curative, but may slow disease progression and improve quality of life. Patients with severe emphysema or frequent exacerbations may be candidates for investigational stem cell trials or therapy abroad.
🔬 Scientific Evidence: Regenerative Therapies for COPD
Study: Weiss et al., 2013
This phase I trial involved 62 patients with moderate-to-severe COPD who received allogeneic MSCs intravenously. The treatment was well tolerated with no serious adverse events. Treated patients had fewer exacerbations and lower levels of systemic inflammation markers compared to placebo. PubMed
Glossary
- COPD: Chronic Obstructive Pulmonary Disease, a group of progressive lung diseases...